Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.39 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4080236 | 0.91 | CNR1 (0.55) | GRIN2BCNR1FAAHCNR2 | |
| SCHEMBL5800452 | 0.90 | DPP4 (0.41) | GRIN2BCNR1RBP4CACNA1H | |
| SCHEMBL5780334 | 0.89 | CNR1 (0.41) | CNR1FAAHCNR2 | |
| SCHEMBL5800214 | 0.85 | FAAH (0.40) | CNR1FAAHCNR2RBP4 | |
| SCHEMBL4075822 | 0.84 | CNR1 (0.44) | GRIN2BCNR1FAAHRBP4 | |
| SCHEMBL4079038 | 0.83 | GRIN2B (0.62) | GRIN2BCNR1FAAHCNR2CACNA2D1 | |
| SCHEMBL4075719 | 0.83 | GRIN2B (0.62) | GRIN2BCNR1FAAHCNR2CACNA2D1 | |
| SCHEMBL4088616 | 0.82 | CNR1 (0.62) | CNR1FAAHCNR2 | |
| SCHEMBL29574408 | 0.82 | CNR1 (0.62) | CNR1FAAHCNR2 | |
| SCHEMBL4075585 | 0.82 | GRIN2B (0.56) | GRIN2BCNR1FAAHCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620395-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096763-A1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |